(2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane structure
|
Common Name | (2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane | ||
---|---|---|---|---|
CAS Number | 119302-24-8 | Molecular Weight | 488.702 | |
Density | 1.2±0.1 g/cm3 | Boiling Point | 574.1±50.0 °C at 760 mmHg | |
Molecular Formula | C29H48N2O4 | Melting Point | N/A | |
MSDS | N/A | Flash Point | 301.0±30.1 °C |
Name | (2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane |
---|---|
Synonym | More Synonyms |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 574.1±50.0 °C at 760 mmHg |
Molecular Formula | C29H48N2O4 |
Molecular Weight | 488.702 |
Flash Point | 301.0±30.1 °C |
Exact Mass | 488.361420 |
PSA | 62.24000 |
LogP | 3.80 |
Vapour Pressure | 0.0±3.6 mmHg at 25°C |
Index of Refraction | 1.574 |
HS Code | 2942000000 |
---|
~71% (2b,3a,5a,16b,1... CAS#:119302-24-8 |
Literature: Mendez, Juana Araceli; De La Mora, Marco A.; Rodriguez, Angel A.; Barragan, Efrain; Herrera, Hugo; Guillen, Alejandro Patent: US2007/117975 A1, 2007 ; Location in patent: Page/Page column 15 ; |
~92% (2b,3a,5a,16b,1... CAS#:119302-24-8 |
Literature: GLAND PHARMA LIMITED Patent: WO2009/16648 A2, 2009 ; Location in patent: Page/Page column 8-9 ; |
~21% (2b,3a,5a,16b,1... CAS#:119302-24-8 |
Literature: US2005/159398 A1, ; Page/Page column 8 ; |
~% (2b,3a,5a,16b,1... CAS#:119302-24-8 |
Literature: US2005/159398 A1, ; Page/Page column 8 ; |
~% (2b,3a,5a,16b,1... CAS#:119302-24-8
Detail
|
Literature: US2007/117975 A1, ; Page/Page column 16 ; |
HS Code | 2942000000 |
---|
RocuroniuM BroMide InterMediate VIII |
(2β,3α,5α,16β,17β)-3-Hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstan-17-yl acetate |
Androstane-3,17-diol, 2-(4-morpholinyl)-16-(1-pyrrolidinyl)-, 17-acetate, (2β,3α,5α,16β,17β)- |
(2β,3α,5α,16β,17β)-3-Hydroxy-2-(morpholin-4-yl)-16-(pyrrolidin-1-yl)androstan-17-yl acetate |
(2b,3a,5a,16b,17b)-17-Acetoxy-3-hydroxy-2-(4-morpholinyl)-16-(1-pyrrolidinyl)androstane |